Iovance Biotherapeutics (IOVA)

Company Profile

iovance biotherapeutics is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (til). this approach, also known as adoptive t-cell therapy, was initially developed by dr. steven a. rosenberg at the national cancer institute (nci). in phase 2 clinical trials conducted at the nci, 56% and 24% of patients treated with this technology were reported by nci to have achieved objective and complete response criteria, respectively. our lead product candidate is an autologous, ready-to-infuse cell therapy, that has demonstrated distinctive efficacy in the treatment of metastatic melanoma. in addition to metastatic melanoma, carcinoma of the head and neck and cervical cancer our til therapy technology is potentially applicable to many other tumor types, including ovarian, breast, bladder, colorectal and other cancers. as we continue advancing our current clinical programs through the introduction of manufacturing and logistical

Company profile

Ticker

IOVA

Exchange

NASDAQ

Website

iovance.com

CEO

Maria Fardis

Incorporated

Delaware

Location

California

Fiscal year end

Dec 31

Sector

Manufacturing > Biological Product (except Diagnostic) Manufacturing

Industry (SIC)

Biological Products, (No Diagnostic Substances)

AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Ginkgo Bioworks • Exelixis • Acorda Therapeutics ...

Former names

FREIGHT MANAGEMENT CORP, Genesis Biopharma, Inc, Lion Biotechnologies, Inc.

SEC CIK

0001425205

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Iovance Biotherapeutics GmbH, a company • Iovance Biotherapeutics B.V., a company • Iovance Biotherapeutics Manufacturing LLC, a limited liability company • Iovance Biotherapeutics UK Ltd, a limited company • Iovance Biotherapeutics Canada Inc., a company ...

IRS number

753254381

IOVA stock data

1M 1Y 5Y

Latest filings (excl ownership)

View all

8-K

U.S. Food and Drug Administration Updates

15 Sep 23

8-K

Regulation FD Disclosure

8 Aug 23

Iovance Biotherapeutics Reports Second Quarter and First Half 2023

8 Aug 23

8-K

Iovance Biotherapeutics Announces Closing of $172.5 Million Common Stock Public Offering

13 Jul 23

424B5

Prospectus supplement for primary offering

11 Jul 23

8-K

Iovance Biotherapeutics, Inc. Announces Proposed Public Offering of Common Stock

11 Jul 23

424B5

Prospectus supplement for primary offering

10 Jul 23

8-K

Results of Operations and Financial Condition

10 Jul 23

8-K

Iovance Biotherapeutics Announces Regulatory and Clinical Updates for TIL Therapy in Advanced Non-Small Cell Lung Cancer

10 Jul 23

Transcripts

View all

IOVA

Earnings call transcript

2023 Q2

8 Aug 23

IOVA

Earnings call transcript

2023 Q1

9 May 23

IOVA

Earnings call transcript

2022 Q4

28 Feb 23

IOVA

Earnings call transcript

2022 Q3

4 Nov 22

IOVA

Earnings call transcript

2022 Q2

5 Aug 22

IOVA

Earnings call transcript

2022 Q1

6 May 22

IOVA

Earnings call transcript

2021 Q4

25 Feb 22

IOVA

Earnings call transcript

2021 Q3

5 Nov 21

IOVA

Earnings call transcript

2021 Q2

6 Aug 21

IOVA

Earnings call transcript

2021 Q1

7 May 21

Latest ownership filings

View all

FINCKENSTEIN FRIEDRICH GRAF

Financial summary

Financial statements Chart IOVA financial data

Quarter (USD)	Jun 23	Mar 23	Dec 22	Sep 22
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 22	Dec 21	Dec 20	Dec 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	296.44 mm	296.44 mm	296.44 mm	296.44 mm	296.44 mm	296.44 mm
Cash burn (monthly)	84.49 mm	(no burn)	36.70 mm	35.70 mm	31.32 mm	27.92 mm
Cash used (since last report)	238.30 mm	n/a	103.49 mm	100.68 mm	88.33 mm	78.76 mm
Cash remaining	58.14 mm	n/a	192.95 mm	195.76 mm	208.11 mm	217.68 mm
Runway (months of cash)	0.7	n/a	5.3	5.5	6.6	7.8

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q2 2023

IOVA institutional ownership history Ownership history

89.9% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	217	220	-1.4%
Opened positions	34	37	-8.1%
Closed positions	37	35	+5.7%
Increased positions	88	86	+2.3%
Reduced positions	63	61	+3.3%

13F shares	Current	Prev Q	Change
Total value	1.40 tn	1.20 tn	+17.1%
Total shares	222.77 mm	218.32 mm	+2.0%
Total puts	591.10 k	794.90 k	-25.6%
Total calls	915.30 k	784.70 k	+16.6%
Total put/call ratio	0.6	1.0	-36.2%

Largest owners	Shares	Value	Change
Vanguard	20.40 mm	$143.58 bn	+50.6%
Quogue Capital	20.00 mm	$136.80 mm	0.0%
BLK Blackrock	17.00 mm	$119.69 bn	+36.5%
Perceptive Advisors	14.04 mm	$98.82 bn	-8.5%
STT State Street	13.57 mm	$95.50 bn	-1.2%
MHR Fund Management	12.00 mm	$84.46 bn	0.0%
Point72 Asset Management	7.79 mm	$54.82 bn	-11.5%
Avoro Capital Advisors	6.70 mm	$47.17 bn	-4.6%
Pictet Asset Management	5.18 mm	$36.43 bn	+436.7%
Orbimed Advisors	4.71 mm	$33.14 bn	0.0%

Largest transactions	Shares	Bought/sold	Change
Vanguard	20.40 mm	+6.86 mm	+50.6%
BLK Blackrock	17.00 mm	+4.55 mm	+36.5%
Pictet Asset Management	5.18 mm	+4.21 mm	+436.7%
MS Morgan Stanley	3.50 mm	-4.20 mm	-54.5%
Millennium Management	3.58 mm	+3.58 mm	NEW
BEN Franklin Resources	18.34 k	-2.68 mm	-99.3%
Deutsche Bank AG - Registered Shares	3.31 mm	+2.39 mm	+258.2%
Citadel Advisors	1.33 mm	-2.14 mm	-61.6%
Hood River Capital Management	1.98 mm	+1.98 mm	NEW
Deerfield Management	0.00	-1.83 mm	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

IOVA insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
18 Sep 23	Mcpeak Merrill A	Common Stock	Buy	Acquire P	Yes	No	5.56	10,000	55.60 k	248,633
15 Sep 23	Wayne P. Rothbaum	Common Stock	Buy	Acquire P	Yes	No	5.3	5,000,000	26.50 mm	23,067,333
14 Jul 23	Frederick G Vogt	Common Stock	Payment of exercise	Dispose F	No	No	7.76	8,851	68.68 k	72,850
14 Jul 23	Frederick G Vogt	Common Stock	Option exercise	Acquire M	No	No	0	20,834	0.00	81,701
14 Jul 23	Frederick G Vogt	RSU Common stock	Option exercise	Dispose M	No	No	0	20,834	0.00	125,007
14 Jul 23	Finckenstein Friedrich Graf	Common Stock	Payment of exercise	Dispose F	No	No	7.76	1,395	10.83 k	30,953
14 Jul 23	Finckenstein Friedrich Graf	Common Stock	Option exercise	Acquire M	No	No	0	2,813	0.00	32,348
14 Jul 23	Finckenstein Friedrich Graf	RSU Common stock	Option exercise	Dispose M	No	No	0	2,813	0.00	16,877
14 Jul 23	Bilinsky Igor	Common Stock	Payment of exercise	Dispose F	No	No	7.76	1,395	10.83 k	27,213
14 Jul 23	Bilinsky Igor	Common Stock	Option exercise	Acquire M	No	No	0	2,813	0.00	28,608